Yonghe Medical Group And 2 Other Promising Penny Stocks In Global

Global markets have recently shown resilience, with U.S. equity markets rallying on the back of strong corporate earnings and a robust labor market, while European and Asian indices have also seen notable gains. Amid these broad market movements, investors continue to seek opportunities that balance risk and reward. Penny stocks, though often seen as relics of past trading days, remain relevant for those looking to invest in smaller or newer companies that can offer surprising value when built on solid financial foundations.

Top 10 Penny Stocks Globally

Click here to see the full list of 3,499 stocks from our Global Penny Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Yonghe Medical Group (SEHK:2279)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Yonghe Medical Group Co., Ltd. operates in China, offering hair-related healthcare services, with a market cap of HK$1.17 billion.

Operations: The company generates revenue of CN¥1.81 billion from its hair transplant services.

Market Cap: HK$1.17B

Yonghe Medical Group, with a market cap of HK$1.17 billion, has shown significant financial improvement by becoming profitable over the past year, reporting a net income of CN¥73.71 million for 2025 compared to a net loss in 2024. The company is trading at an attractive value below its estimated fair value and has no debt on its balance sheet. Despite having low return on equity at 9.3%, Yonghe's efficient management and optimized business model have enhanced operating efficiency, contributing to higher gross profit margins and reduced expense ratios. However, its dividend track record remains unstable.

• Click to explore a detailed breakdown of our findings in Yonghe Medical Group's financial health report.
• Assess Yonghe Medical Group's future earnings estimates with our detailed growth reports.

Fujian Aonong Biological Technology Group Incorporation (SHSE:603363)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Fujian Aonong Biological Technology Group Incorporation Limited operates in feed production, pig farming, food, and supply chain services both in China and internationally with a market cap of CN¥8.28 billion.

Operations: Fujian Aonong Biological Technology Group Incorporation Limited has not reported specific revenue segments.

Market Cap: CN¥8.28B

Fujian Aonong Biological Technology Group Incorporation Limited, with a market cap of CN¥8.28 billion, has seen its financial performance fluctuate. Despite reporting sales of CN¥2.21 billion for Q1 2026, the company experienced a net loss of CN¥13.33 million compared to a net income in the previous year. Although unprofitable, Fujian Aonong has reduced its debt to equity ratio significantly over five years and maintains a positive cash flow with sufficient runway for over three years. However, short-term liabilities exceed assets by CN¥0.3 billion, and management tenure is relatively short at 2.3 years on average.

• Navigate through the intricacies of Fujian Aonong Biological Technology Group Incorporation with our comprehensive balance sheet health report here.
• Learn about Fujian Aonong Biological Technology Group Incorporation's historical performance here.

Baoxiniao Holding (SZSE:002154)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Baoxiniao Holding Co., Ltd. focuses on the research, development, production, and sale of branded men's and women's clothing products in China with a market cap of CN¥6.58 billion.

Operations: There are no reported revenue segments for Baoxiniao Holding Co., Ltd.

Market Cap: CN¥6.58B

Baoxiniao Holding Co., Ltd. reported a slight decrease in annual net income, from CN¥494.96 million to CN¥341.75 million, despite stable revenue figures around CN¥5 billion for 2025. The company benefits from a seasoned management team and board with average tenures of 8.8 and 7.5 years respectively, ensuring experienced oversight. Baoxiniao's financial health is supported by short-term assets exceeding both short-term and long-term liabilities, while its debt level is comfortably covered by cash flow and interest payments are not a concern. However, the company's earnings growth has been negative over the past year amidst an unstable dividend track record.

• Jump into the full analysis health report here for a deeper understanding of Baoxiniao Holding.
• Explore Baoxiniao Holding's analyst forecasts in our growth report.

Taking Advantage

• Gain an insight into the universe of 3,499 Global Penny Stocks by clicking here.
• Curious About Other Options? This technology could replace computers: discover the 27 stocks are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com